EOLS Company Profile and Key Details

EOLS has shown weak momentum, losing -12.31% over the past week and -20.94% over the past quarter, though year-to-date performance is down -23.91%. Short-term trend indicators are bullishly aligned (SMA20 0.71%, SMA50 -16.72%, SMA200 -37.97%). The stock’s 14-day RSI is 42.53 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.95% below its high and over 9.75% above its low. Average 10-day trading volume of 1.36 million shares is significantly above the 3-month average of 896.60 thousand, indicating heightened recent market interest.

Evolus, Inc. generated EPS of -$0.91 over the past year. Five-year average earnings growth is 23.91%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at $0.03. Next year's EPS is expected at $17.67. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $13.00. The high target offers 244.29% upside. The low target suggests 103.44% downside. The mean target is $17.40. This offers 172.3% upside. Evolus, Inc. earnings surprise history is a mixed track record. The quarter that ended May 04, 2026, missed forecasts by -67.33%. The prior quarter beat by -26.3%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in March 04, 2025.

Evolus, Inc. has 64.69 million shares outstanding. The public float is 50.60 million shares, elevated short interest at 21.30% of float. This equals 13.48 million shares. The short ratio is 14.62 days. Institutional investors hold 103.29% of the float. Insiders own 11.81%. Alphaeon Corp holds 8.66 million shares, Alphaeon 1 LLC has 4.21 million shares and Medytox Inc. has 3.38 million shares. Over the past six months, insider transactions show net selling. They sold 176.30 thousand shares across 6 transactions.

Evolus, Inc. (NASDAQ:EOLS) closed at $6.39 USD, gaining $0.07 (1.11%) from the previous close of $6.32. The stock is currently mid-range between its 52-week high and low $3.86 and $11.42. With a market capitalization of about $420.81 million, Evolus, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.29). Key stats such as the average daily volume over the past year has been around 1.12 million shares, in line with its 52-week average. Headquartered in Newport Beach, CA, Evolus, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David Moatazedi, the company employs approximately 372 people and listed since February 08, 2018. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.

Evolus, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.05. This means the shares are trading below this model’s fair value.

Evolus, Inc. trades at a P/E ratio of -9.7, slightly below the S&P 500 average, with a price-to-sales ratio of 1.41 and a price-to-book ratio of -14.63 indicating negative book value, which may reflect financial stress. The P/FCF stands at -10.29, also below market averages.

Our AI price prediction model suggests that Evolus, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.74%, with price expected at $7.14 by May 20, 2026, within a range of $6.90 to $7.36 3-Month Outlook: Projected fall of -47.89%, reaching $3.33 by August 04, 2026, with a range of $2.50 to $3.69. 1-Year Outlook: Projected gain of 12.68%, with price at $7.20 by May 06, 2027, within a range of $0.00 to $7.83.

Evolus, Inc. (NASDAQ:EOLS) shares are down -23.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evolus, Inc. trading at a premium to the broader market with a P/E of -9.7. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.12, suggesting 214.87% upside. Our AI forecast model points to short-term strength (11.74% over two weeks), a medium-term fall (-47.89% over three months), and a longer-term gain (12.68% over one year), with expected trading ranges indicating moderate volatility.